Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434428 | 0.98 | CNR1 (0.60) | CNR1ALDH1A1NPSR1HPGDCNR2 | |
| SCHEMBL2334318 | 0.83 | NAAA (0.72) | CNR1CNR2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1233128 | 0.82 | CYP3A4 (0.63) | CNR1ALDH1A1NPSR1CNR2HTT | |
| SCHEMBL6434483 | 0.81 | NAAA (0.75) | CNR1ALDH1A1CNR2HTTCYP3A4 | |
| SCHEMBL2333785 | 0.81 | NAAA (0.75) | CNR1ALDH1A1CNR2HTTCYP3A4 | |
| SCHEMBL6436285 | 0.81 | CNR1 (0.69) | CNR1CNR2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17749476 | 0.80 | CNR1 (0.67) | CNR1CNR2HTTSMN1; SMN2 | |
| SCHEMBL7603553 | 0.79 | CNR1 (0.71) | CNR1CNR2HTTSMN1; SMN2 | |
| SCHEMBL5100260 | 0.78 | CNR1 (0.57) | CNR1ALDH1A1NPSR1CNR2HTT | |
| Hydrochloric Acid SCHEMBL5099409 | 0.78 | CNR1 (0.65) | CNR1CNR2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |